Anticancer Drug Discovery and Development: Natural Products and New Molecular Models: Proceedings of the Second Drug Discovery and Development ... 27–29, 1991 (Developments in Oncology, 74). Cet article n’est pas disponible.
Langue : anglais
Edité par Springer, 1994
- Livre relié
- Neuf
Vendeur : Ria Christie Collections, Uxbridge, Royaume-UniRia Christie Collections
Vendeur avec une évaluation de 5 étoiles
Vendeur AbeBooks depuis 25 mars 2015
Indisponible
Livre relié
Etat: Neuf
EUR 354,35
A propos de cet article
In English.
N° de réf. du vendeur ria9780792329282_new
- Titre
- Anticancer Drug Discovery and Development: Natural Products and New Molecular Models: Proceedings of the Second Drug Discovery and Development ... 27–29, 1991 (Developments in Oncology, 74)
- Éditeur
- Springer
- Année de publication
- 1994
- État de l'article
- New
- Reliure
- Couverture rigide
- Langue
- anglais
- ISBN à 10 chiffres
- 0792329287
- ISBN à 13 chiffres
- 9780792329282
- Poids de l'article
- 884 grammes
- Série
- Livre 69 sur 78: Developments in Oncology
With the publication of these proceedings from the Second Drug Discovery and Development Symposium, this forum has become the main mechanism for bringing together the principal groups involved in both discovering and developing new approaches to the treatment of cancer. This Second Symposium emphasized the types of materials being discovered and their therapeutic activity. This is especially evident in the natural product discovery programs, where unique and active structures are being identified.
The major contributors to the meeting were the investigators participating in the National Cooperative (Natural Products) Drug Discovery Groups [NC(NP)DDG]. These groups reflect an association among researchers at universities or cancer centers, pharmaceutical companies and the National Cancer Institute. Their sources of materials are varied, reflecting chemical inventories of pharmaceutical companies, organic synthetic compounds from the laboratory, cytotoxics as well as biologics and their hybrids, and natural products obtained from plants, marine organisms and microorganisms. The models employed in the discovery systems vary from broadly cellular based to specific enzymes to defined cellular functions. Each of them is believed important to the malignant state and will allow for the discovery of compounds which will have efficacy in cancer therapy.
The goal of the participants is both to discover new anticancer agents and to develop them as efficiently as possible into clinically useful additions to treatment. Of importance is the fact that there are a number of promising leads which will soon be moving into the clinic thereby testing the effectiveness of this NC (NP) DDG approach.
The major contributors to the meeting were the investigators participating in the National Cooperative (Natural Products) Drug Discovery Groups [NC(NP)DDG]. These groups reflect an association among researchers at universities or cancer centers, pharmaceutical companies and the National Cancer Institute. Their sources of materials are varied, reflecting chemical inventories of pharmaceutical companies, organic synthetic compounds from the laboratory, cytotoxics as well as biologics and their hybrids, and natural products obtained from plants, marine organisms and microorganisms. The models employed in the discovery systems vary from broadly cellular based to specific enzymes to defined cellular functions. Each of them is believed important to the malignant state and will allow for the discovery of compounds which will have efficacy in cancer therapy.
The goal of the participants is both to discover new anticancer agents and to develop them as efficiently as possible into clinically useful additions to treatment. Of importance is the fact that there are a number of promising leads which will soon be moving into the clinic thereby testing the effectiveness of this NC (NP) DDG approach.
« Synopsis » peut appartenir à une autre édition de cet ouvrage.